DSIP, a chain of nine amino acids sold as an injectable research product for sleep, stress resilience and healthy aging, has promised benefits unconfirmed in people. Its discoverers reported better sleep, but independent controlled studies found only small changes. Longevity evidence rests entirely on animal studies. Reported side effects were mild in the few hundred people studied over weeks; unregulated manufacturing and combining with other sleep-promoting drugs pose larger risks. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Insomnia Severity Index (ISI) | 0–7 | Primary insomnia outcome |
| Sleep efficiency | ≥90% | Main outcome in DSIP trials |
| Sleep onset latency | 10–20 min | Tracks faster sleep onset |
| Deep (slow-wave) sleep | No established target; track change from own baseline | DSIP's proposed target |
| Apnea–hypopnea index (AHI) | <5 events/hour | Excludes sleep apnea before use |
| Fasting glucose | 75–90 mg/dL | Claimed glucose effects |
| HbA1c | 4.8–5.4% | Three-month glucose average |
| Morning cortisol | 10–18 µg/dL | Claimed stress-hormone effects |
| ALT | <25 U/L | Liver safety of unregulated injectable |
| eGFR | >90 mL/min/1.73 m² | Kidney function baseline |
Cadence: Baseline (including at least one week of sleep-diary or wearable data); at 1 week and 2 weeks into each course (sleep questionnaire, diary or wearable, morning alertness); every 3–6 months for repeated courses (blood tests)